| 1 |
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,266 |
| 2 |
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al. · New England Journal of Medicine
Open access |
19 Apr 2015 |
5,968 |
| 3 |
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al. · New England Journal of Medicine
Open access |
11 Sep 2017 |
5,453 |
| 4 |
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al. · New England Journal of Medicine
Open access |
16 Nov 2014 |
5,431 |
| 5 |
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al. · Nature
Open access1,384 authors |
5 Feb 2020 |
3,854 |
| 6 |
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
3,784 |
| 7 |
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid et al. · New England Journal of Medicine
Open access |
2 Jun 2013 |
3,425 |
| 8 |
Pan-cancer analysis of whole genomes
Lauri A. Aaltonen et al. · Nature
Open access1,324 authors |
5 Feb 2020 |
3,360 |
| 9 |
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al. · New England Journal of Medicine
Open access |
30 Sep 2012 |
2,838 |
| 10 |
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al. · New England Journal of Medicine
Open access |
16 Nov 2014 |
2,718 |
| 11 |
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
Daniel Y. Wang et al. · JAMA Oncology
Open access |
18 Sep 2018 |
2,692 |
| 12 |
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Charles M. Balch, Seng‐Jaw Soong, Jeffrey E. Gershenwald et al. · Journal of Clinical Oncology
|
15 Aug 2001 |
2,418 |
| 13 |
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess et al. · CA A Cancer Journal for Clinicians
Open access |
13 Oct 2017 |
2,317 |
| 14 |
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber et al. · New England Journal of Medicine
Open access |
10 Sep 2017 |
2,249 |
| 15 |
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Elizabeth Ann Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine
Open access |
Jun 1982 |
2,216 |
| 16 |
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey Alan Sosman et al. · New England Journal of Medicine
Open access |
22 Feb 2012 |
2,170 |
| 17 |
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont et al. · New England Journal of Medicine
Open access |
15 Apr 2018 |
1,906 |
| 18 |
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al. · The Lancet
|
14 Jul 2014 |
1,779 |
| 19 |
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al. · The Lancet Oncology
Open access |
24 Jun 2015 |
1,581 |
| 20 |
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al. · Nature
Open access |
May 2017 |
1,548 |
| 21 |
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor J. Puzanov et al. · Cell
Open access |
Sep 2017 |
1,523 |
| 22 |
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
Melina Arnold, Deependra Singh, Mathieu Laversanne et al. · JAMA Dermatology
Open access |
30 Mar 2022 |
1,520 |
| 23 |
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
Georgina Venetia Long et al. · New England Journal of Medicine
Open access |
10 Sep 2017 |
1,501 |
| 24 |
Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
Donald L. Morton, John F. Thompson, Alistair J. Cochran et al. · New England Journal of Medicine
Open access |
12 Feb 2014 |
1,490 |
| 25 |
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina Venetia Long et al. · The Lancet
|
31 May 2015 |
1,419 |
| 26 |
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries et al. · New England Journal of Medicine
Open access |
7 Jun 2017 |
1,415 |
| 27 |
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert et al. · New England Journal of Medicine
Open access |
4 Jun 2019 |
1,412 |
| 28 |
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke, Keith T. Flaherty, Antoni Ribas et al. · Nature Reviews Clinical Oncology
Review |
4 Apr 2017 |
1,316 |
| 29 |
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina Venetia Long et al. · The Lancet
|
16 Aug 2017 |
1,256 |
| 30 |
Immune checkpoint inhibitors in melanoma
Matteo Salvatore Carlino, James Larkin, Georgina Venetia Long · The Lancet
|
Sep 2021 |
1,231 |
| 31 |
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology
Open access |
22 Jul 2019 |
1,179 |
| 32 |
The evolutionary history of 2,658 cancers
Moritz Gerstung et al. · Nature
Open access1,441 authors |
5 Feb 2020 |
1,149 |
| 33 |
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al. · Journal of Clinical Oncology
Open access |
24 Nov 2021 |
1,144 |
| 34 |
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba Nur Gide et al. · Cancer Cell
Open access |
Feb 2019 |
1,086 |
| 35 |
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al. · JAMA
Open access |
19 Apr 2016 |
1,081 |
| 36 |
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Jeanne Tie et al. · New England Journal of Medicine
Open access |
4 Jun 2022 |
1,076 |
| 37 |
An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
Katherine Stemke‐Hale et al. · Cancer Research
Open access |
Aug 2008 |
1,054 |
| 38 |
Patterns of somatic structural variation in human cancer genomes
Yilong Li et al. · Nature
Open access1,411 authors |
5 Feb 2020 |
1,005 |
| 39 |
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina Venetia Long, Victoria G. Atkinson, Serigne Lo et al. · The Lancet Oncology
|
27 Mar 2018 |
1,005 |
| 40 |
Caveolae: From Cell Biology to Animal Physiology
Babak Razani, Scott Eric Woodman, Michael P. Lisanti · Pharmacological Reviews
|
Sep 2002 |
994 |
| 41 |
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Venetia Long, Reinhard Dummer, Omid Hamid et al. · The Lancet Oncology
|
17 Jun 2019 |
991 |
| 42 |
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Omid Hamid, Caroline Robert, ADIL I. DAUD et al. · Annals of Oncology
Open access |
29 Jan 2019 |
961 |
| 43 |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald Steven Falchook, Georgina Venetia Long, Razelle Kurzrock et al. · The Lancet
Open access |
May 2012 |
946 |
| 44 |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina Venetia Long et al. · The Lancet Oncology
|
7 Oct 2012 |
920 |
| 45 |
β-Cell death during progression to diabetes
Diane J. Mathis, Luis Vence, Christophe O. Benoist · Nature
|
Dec 2001 |
887 |
| 46 |
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber et al. · The Lancet
|
21 Jan 2024 |
871 |
| 47 |
Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting
M. Vestergaard, Petra Macaskill, Phoebe E Holt et al. · British Journal of Dermatology
Review |
Jun 2008 |
867 |
| 48 |
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander Maxwell Menzies, Douglas Buckner Johnson, Sangeetha Ramanujam et al. · Annals of Oncology
Open access |
29 Sep 2016 |
831 |
| 49 |
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Imran G. House, Peter Savas, Junyun Lai et al. · Clinical Cancer Research
|
21 Oct 2019 |
815 |
| 50 |
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
Christine Guo Lian et al. · Cell
Open access |
Sep 2012 |
813 |